TICKERNERD
Menu
ATYRATYRHealthcare · Biotechnology

ATYR Stock Forecast: aTyr Pharma, Inc. Price Predictions for 2026-2027

Last close, 29 Oct 2026
$5.37

The 9 Wall Street analysts covering aTyr Pharma, Inc. hold a median 12-month price target of $3 — -44.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 59 of 100 as at 29 Oct 2026 — in the upper half.

Market cap
$12.3M
Ticker Nerd rank
59/ 100
Median analyst target
$3.00
Analysts covering
9
Revenue$0.0
Operating income−$10.9M
Net income−$10.3M
Free cash flow−$9.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Ticker Nerd rank

ATYR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores aTyr Pharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 29 Oct 2026
59/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
89
Issuance
87
Growth
84
Accruals
77
Revisions
63
Volatility
43
Quality
30
Value
7
Momentum
7

Size (89): Smaller than most of the companies we track.

Momentum (7): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ATYR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ATYR, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says9 analysts
4 Buy5 Hold0 Sell
Low $1.00Median $3.00High $7.00

The green dot is the last close — the median target sits −44.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
20 May 2026Freedom BrokerUpgradeBuy$1.00 → $3.50
7 Nov 2025RBC CapitalMaintainsSector Perform—
16 Sept 2025RBC CapitalDowngradeSector Perform—
16 Sept 2025Wells FargoDowngradeEqual-Weight—
15 Sept 2025Cantor FitzgeraldDowngradeNeutral—
15 Sept 2025HC Wainwright & Co.DowngradeNeutral—
15 Sept 2025Jones TradingDowngradeHold—
15 Sept 2025Leerink PartnersDowngradeMarket Perform—
15 Sept 2025LUCID CAPITAL MARKETSDowngradeNeutral—
22 Aug 2025JefferiesMaintainsBuy—
20 June 2025Wells FargoMaintainsOverweight—
4 June 2025HC Wainwright & Co.ReiteratesBuy—
19 May 2025HC Wainwright & Co.ReiteratesBuy—
14 Mar 2025HC Wainwright & Co.ReiteratesBuy—
18 Feb 2025Leerink PartnersInitiatesOutperform—
6 Jan 2025Cantor FitzgeraldInitiatesOverweight—
10 Dec 2024HC Wainwright & Co.ReiteratesBuy—
3 Dec 2024HC Wainwright & Co.ReiteratesBuy—
29 Oct 2024HC Wainwright & Co.ReiteratesBuy—
4 Oct 2024Wells FargoInitiatesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

ATYR appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Estimates

ATYR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
4
Analysts cutting
0
Fundamentals

aTyr Pharma, Inc. (ATYR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−6.2×

Cheaper than 78% of US stocks

Price / sales
65.0×

Cheaper than 4% of US stocks

Price / book
0.2×

Cheaper than 87% of US stocks

EV / EBITDA
0.5×

Cheaper than 59% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
−33609.5%

Higher than 1% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−98.7%

Higher than 13% of US stocks

Return on assets
−46.6%

Higher than 9% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

aTyr Pharma, Inc. (ATYR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • aTyr Pharma, Inc. has a market value of $12.3M and an enterprise value of −$33.1M.

  • Revenue in the twelve months to 30 June 2026: $190K.

  • Net income over the same four quarters: −$60.8M, a −32006.3% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.62.

  • Free cash flow in the twelve months to 30 June 2026: −$54.8M.

  • Shares outstanding: 98.1M.

  • Trailing P/E: −6.2×; forward P/E: −0.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • aTyr Pharma, Inc. employs 58 people — $3K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 30 Oct 2026

Data provided by Twelve Data

Peers

ATYR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ATYRaTyr Pharma, Inc.$12.3M59
GUTSFractyl Health, Inc.$13.2M22
DAREDaré Bioscience, Inc.$13.2M30
CNSYCerenome, Inc.$13.2M15
AZRAzora Therapeutics, Inc.$12.8M22
TCRXTScan Therapeutics, Inc.$12.7M54
PBMPsyence Biomedical Ltd.$13.8M4

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own aTyr Pharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ATYR news & analysis

aTyr Pharma Announces Publication of Results from the Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis in The Lancet Respiratory Medicine

GlobeNewsWire · 29 Oct 2026positive

aTyr Pharma announced that results from the Phase 3 EFZO-FIT study of efzofitimod in patients with pulmonary sarcoidosis were published in The Lancet Respiratory Medicine. The company said the publication is available on the journal’s website.

Why it matters — The publication reports on a Phase 3 study of aTyr’s lead therapeutic candidate in pulmonary sarcoidosis.

aTyr Pharma Announces One-for-40 Reverse Stock Split

GlobeNewsWire · 27 Oct 2026neutral

aTyr Pharma announced a 1-for-40 reverse stock split of its issued and outstanding common stock, effective at 5:00 p.m. ET on October 28, 2026.

Why it matters — ATYR watchers may want to note the announced split ratio and effective time.

aTyr Pharma Announces Research Collaboration with Montefiore Einstein

GlobeNewsWire · 19 Oct 2026positive

aTyr Pharma announced a research collaboration with Albert Einstein College of Medicine to further develop and test ATYR2810, its monoclonal antibody targeting the NRP2 receptor. The collaboration will be led by Bang H.

Why it matters — The collaboration concerns further development and testing of aTyr's ATYR2810 program.

aTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects of ATYR0101 in the Journal of Biological Chemistry

GlobeNewsWire · 13 Oct 2026positive

aTyr Pharma announced a Journal of Biological Chemistry publication reporting anti-fibrotic effects of ATYR0101. The company said the candidate is undergoing IND-enabling studies and is expected to advance into the clinic in 2027.

Why it matters — The publication highlights ATYR0101's potential in chronic tissue fibrosis, while its development remains in the preclinical stage.

Positive FDA Alignment Boosts ATyr Pharma's Rare Lung Disease

Benzinga · 24 Sept 2026positive

aTyr Pharma announced it secured a formal agreement with the U.S. Food and Drug Administration regarding the Phase 3 study protocol for its lead therapeutic candidate, efzofitimod, for a rare lung disease. This FDA alignment pertains to the company's investigational drug development program.

Why it matters — A formal FDA agreement on the Phase 3 protocol is a key regulatory milestone for aTyr's lead candidate, efzofitimod, and its rare lung disease program.

FAQ

Frequently asked questions about ATYR stock

What is the ATYR stock price forecast for 2026-2027?

The 9 Wall Street analysts covering aTyr Pharma, Inc. have a median 12-month price target of $3, with estimates ranging from $1 to $7. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ATYR stock a buy right now?

Of the 9 analysts covering aTyr Pharma, Inc., 4 rate it a Buy, 5 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks aTyr Pharma, Inc. 59 out of 100 across roughly 4,600 US stocks as at 29 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ATYR?

As at 29 Oct 2026, aTyr Pharma, Inc. ranks 59 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (89 of 100).

Will ATYR stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies -44.1% from the last close, and Ticker Nerd's factor model ranks aTyr Pharma, Inc. 59 out of 100 as at 29 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ATYR stock forecast for 2030?

No analyst covering aTyr Pharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ATYR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1 to $7 over the next 12 months.

What does aTyr Pharma, Inc. do?

aTyr Pharma, Inc. is a clinical-stage biotechnology company focused on discovering and developing medicines based on tRNA synthetase biology.

What is the latest news on ATYR?

The most recent item we track (GlobeNewsWire, 29 Oct 2026): "aTyr Pharma Announces Publication of Results from the Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis in The Lancet Respiratory Medicine". aTyr Pharma announced that results from the Phase 3 EFZO-FIT study of efzofitimod in patients with pulmonary sarcoidosis were published in The Lancet Respiratory Medicine. The company said the publication is available on the journal’s website.

Company

About aTyr Pharma, Inc.

aTyr Pharma, Inc. is a clinical-stage biotechnology company focused on discovering and developing medicines based on tRNA synthetase biology. The company’s current work centers on efzofitimod, a selective NRP2 modulator being studied for interstitial lung diseases, including pulmonary sarcoidosis and systemic sclerosis-related ILD. aTyr Pharma also advances preclinical programs such as ATYR0101 for fibrosis and ATYR0750 for liver disorders, reflecting a pipeline aimed at inflammation, immune regulation, and tissue remodeling. Headquartered in San Diego, California, and founded in 2005, aTyr Pharma operates as a research-driven biopharmaceutical company with a focus on translating proprietary biology into potential therapeutic candidates for serious fibrotic and inflammatory conditions.

CEO Dr. Sanjay S. Shukla M.D., M.S. · 58 employees · United States · https://atyrpharma.com